Press release
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
- Phase 1 Clinical Trial for Orally Disintegrating Tablet Formulation of Sebetralstat Completed – - Sebetralstat Data Published in the Journal of Medicinal
About this update from Kalvista Pharmaceuticals, Inc.
[{"type":"text","content":"\n- Phase 1 Clinical Trial for Orally Disintegrating Tablet Formulation of Sebetralstat Completed –\n\n- Sebetralstat Data Published in the Journal of Medicinal Chemistry and Xenobiotica –\n\n- Sebetralstat Phase 3 Data Remain on Track for H2 2023 –\n\n CAMBRIDGE, Mass. & SALISBURY, United Kingdom--(BUSINESS WIRE)--\nKalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2022.\n\n“We made a very difficult decision this quarter in terminating our phase 2 KOMPLETE trial for KVD824, but the safety of patients is of utmost importance to our Company,” said Andrew Crockett, Chief Executive Officer of KalVista. “We remain committed to providing best-in-class oral treatments for the hereditary angioedema (HAE) community. We are particularly excited about our recent data for the orally disintegrating tablet (ODT) formulation of sebetralstat, which will enable people to take a dose without requiring chewing or swallowing. We are also pleased with the progress of our Phase 3 KONFIDENT clinical trial for sebetralstat, which remains on our enrollment target for data in the second half of 2023.”\n\nSecond Fiscal Quarter and Recent Business Highlights:\n\n\nPresented at both the Stifel 2022 Healthcare Conference and the Jefferies London Healthcare Conference.\n\n\nReported new patient-focused data at the American College of Allergy Asthma & Immunology (ACAAI) 2022 meeting. The data showed the impact of attacks on mental health, daily activities, and quality of life in people living with HAE and demonstrated the treatment burden associated with on-demand parenteral HAE therapies.\n\n\nAnnounced data from a Phase 1 study of an ODT formulation of sebetralstat. KalVista believes this data supports further development of the formulation, which may have significant benefit for pediatric patients and those who experience difficulty swallowing.\n\n\nPublished new sebetralstat data in both the Journal of Medicinal Chemistry and Xenobiotica, focusing on the medicinal chemistry KalVista conducted that led to the discovery of sebetralstat, and how sebetralstat’s absorption, metabolism, and excretion proper...